KRAS and colorectal carcinoma: Similarly to the KRAS G12C-mutated CRC setting, BRAFV600E inhibition, in this CRC tumor context, showed an immediate upregulation of EGFR, this finding leading to the development of dual-blockade therapeutic strategies with the addition of an EGFR-directed monoclonal antibody [30,31].